Shi et al. found that the HER4–YAP1 axis potentially governs the acquired resistance of HER2-positive GC cells to trastuzumab by promoting epithelial–mesenchymal transition, thereby conferring enhanced proliferative capacity upon HER2-positive GC cells exposed to trastuzumab [26]. Here, ERBB2 is linked to gastric cancer.